View More Recent Stories

Oct 15, 2025 04:08PM Stifel Starts Nuvalent (NUVL) at Buy
Oct 15, 2025 09:31AM Cantor Fitzgerald Starts Nuvalent (NUVL) at Overweight
Oct 13, 2025 12:54PM Nuvalent to present preclinical data for HER2 inhibitor at cancer conference
Oct 4, 2025 04:00PM Why UBS says Q4 is eventful for SMID oncology stocks
Sep 22, 2025 06:34AM Nuvalent Inc (NUVL) completes NDA submission for zidesamtinib
Sep 4, 2025 05:43AM Guggenheim Starts Nuvalent (NUVL) at Buy
Aug 19, 2025 06:16AM Piper Sandler Starts Nuvalent (NUVL) at Overweight
Aug 13, 2025 01:08PM Nuvalent to present pivotal zidesamtinib data at lung cancer conference
Aug 7, 2025 06:34AM Nuvalent, Inc. (NUVL) Misses Q2 EPS by 17c
Aug 7, 2025 06:31AM Nuvalent begins NDA submission for cancer drug zidesamtinib
Jun 30, 2025 04:06PM Goldman Sachs Starts Nuvalent (NUVL) at Buy
Jun 25, 2025 10:12AM Nuvalent (NUVL) PT Raised to $114 at UBS
Jun 25, 2025 06:38AM Nuvalent (NUVL) PT Raised to $130 at H.C. Wainwright
Jun 24, 2025 10:24AM Nuvalent (NUVL) PT Raised to $140 at Leerink Partners
Jun 24, 2025 06:30AM Nuvalent Inc (NUVL) Announces Positive Pivotal Data from ARROS-1 Trial of Zidesamtinib
Jun 18, 2025 04:30PM Nuvalent Inc (NUVL) Appoints Christy Oliger to its Board
May 8, 2025 07:33AM Nuvalent, Inc. (NUVL) Misses Q1 EPS by 5c
Apr 29, 2025 01:11PM Nuvalent Inc (NUVL) Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor
Mar 14, 2025 01:54AM UBS Upgrades Nuvalent (NUVL) to Buy
Mar 3, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Nuvalent (NUVL)
Jan 17, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Nuvalent (NUVL)
Jan 13, 2025 06:34AM Nuvalent Inc (NUVL) Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones
Dec 30, 2024 06:32AM H.C. Wainwright Starts Nuvalent (NUVL) at Buy
Dec 22, 2024 04:00AM Barclays shares outlook for Biotech in 2025, names preferred stocks
Dec 9, 2024 06:31AM Nuvalent Inc (NUVL) Appoints Grant Bogle to Board of Directors
Nov 13, 2024 07:27AM Nuvalent (NUVL) PT Raised to $134 at BMO Capital
Nov 12, 2024 06:31AM Nuvalent, Inc. (NUVL) Misses Q3 EPS by 34c
Oct 24, 2024 03:23AM UBS Starts Nuvalent (NUVL) at Neutral
Sep 17, 2024 06:15AM Nuvalent Inc (NUVL) Prices Upsized 5M Share Offering at $100/sh
Sep 16, 2024 08:57AM TD Cowen Reiterates Buy Rating on Nuvalent (NUVL)
Sep 16, 2024 08:06AM Nuvalent (NUVL) PT Raised to $135 at Stifel
Sep 16, 2024 07:45AM Piper Sandler Reiterates Overweight Rating on Nuvalent (NUVL)
Sep 16, 2024 07:02AM Nuvalent (NUVL) Announces Public Offering of Common Stock
Sep 13, 2024 09:54AM Nuvalent Inc (NUVL) Announces Publication in Cancer Discovery Detailing Design and Characterization of NVL-655
Sep 10, 2024 06:33AM Baird Reiterates Outperform Rating on Nuvalent (NUVL)
Sep 10, 2024 05:08AM Jefferies Reiterates Buy Rating on Nuvalent (NUVL)
Sep 9, 2024 11:57AM Piper Sandler Reiterates Overweight Rating on Nuvalent (NUVL)
Sep 9, 2024 06:31AM Nuvalent Inc (NUVL) Reports Latest Data on NVL-655
Sep 6, 2024 11:49AM Barclays Reiterates Overweight Rating on Nuvalent (NUVL), PT $100
Aug 30, 2024 07:06AM Piper Sandler Reiterates Overweight Rating on Nuvalent (NUVL)
Aug 29, 2024 03:42AM Barclays Starts Nuvalent (NUVL) at Overweight
Aug 8, 2024 06:35AM Nuvalent, Inc. (NUVL) Misses Q2 EPS by 12c
Jul 11, 2024 06:30AM Nuvalent Inc (NUVL) Appoints Henry Pelish as Chief Scientific Officer
Jul 9, 2024 04:09PM Nuvalent (NUVL) PT Raised to $115 at Stifel
View More Recent Stories